Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.

Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A.

Mol Oncol. 2014 Mar;8(2):250-60. doi: 10.1016/j.molonc.2013.11.005. Epub 2013 Dec 1.

2.

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.

Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S.

J Am Acad Dermatol. 2014 Dec;71(6):1102-1109.e1. doi: 10.1016/j.jaad.2014.09.002. Epub 2014 Oct 16.

3.

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.

Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT.

Melanoma Res. 2016 Feb;26(1):83-7. doi: 10.1097/CMR.0000000000000214.

PMID:
26731560
4.

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.

Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL Jr, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA.

JAMA Oncol. 2016 Aug 1;2(8):1056-64. doi: 10.1001/jamaoncol.2016.0509.

5.

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.

Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.

Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.

6.

p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.

Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.

Eur J Cancer. 2016 Mar;55:98-110. doi: 10.1016/j.ejca.2015.12.002. Epub 2016 Jan 17.

PMID:
26790143
7.

Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.

Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R; Dermatology Cooperative Oncology Group (DeCOG).

Eur J Cancer. 2014 Jan;50(2):406-10. doi: 10.1016/j.ejca.2013.09.014. Epub 2013 Oct 29.

PMID:
24183461
8.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.

Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.

PMID:
26433819
9.

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.

Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Peñas P.

JAMA Dermatol. 2015 Oct;151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745.

PMID:
26200476
10.

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.

Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.

Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16.

11.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.

N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.

12.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.

Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712.

13.

Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.

Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK.

J Clin Invest. 2014 Mar;124(3):1406-17. doi: 10.1172/JCI70454. Epub 2014 Feb 24.

14.

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.

Hartman ML, Rozanski M, Osrodek M, Zalesna I, Czyz M.

Lab Invest. 2017 Feb;97(2):217-227. doi: 10.1038/labinvest.2016.140. Epub 2017 Jan 9.

PMID:
28067893
15.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R.

N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.

16.

Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.

Sufficool KE, Hepper DM, Linette GP, Hurst EA, Lu D, Lind AC, Cornelius LA.

J Cutan Pathol. 2014 Jul;41(7):568-75. doi: 10.1111/cup.12346. Epub 2014 Apr 29.

PMID:
24641301
17.

Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.

Hartsough EJ, Basile KJ, Aplin AE.

Mol Cancer Res. 2014 May;12(5):795-802. doi: 10.1158/1541-7786.MCR-13-0581. Epub 2014 Feb 11.

18.

Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.

King JW, Nathan PD.

Future Oncol. 2014;10(9):1559-70. doi: 10.2217/fon.14.89. Review.

PMID:
25145427
19.

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

Scholtens A, Geukes Foppen MH, Blank CU, van Thienen JV, van Tinteren H, Haanen JB.

Eur J Cancer. 2015 Mar;51(5):642-52. doi: 10.1016/j.ejca.2015.01.009. Epub 2015 Feb 15.

PMID:
25690538
20.

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.

Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De Vitis C, Pisanu ME, Coluccia P, Camerlingo R, Roscilli G, Ribas A, Di Napoli A, Torrisi MR, Aurisicchio L, Ascierto PA, Mancini R, Ciliberto G.

Oncotarget. 2015 Sep 22;6(28):24823-41. doi: 10.18632/oncotarget.4485.

Supplemental Content

Support Center